Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -53.08% | -99.87% | -99.89% | -99.92% | -99.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.08% | -99.87% | -99.89% | -99.92% | -99.85% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -53.08% | -99.87% | -99.89% | -99.92% | -99.85% |
| SG&A Expenses | -22.31% | -36.77% | -40.02% | -40.10% | -42.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -31.17% | -15.13% | 20.54% | 38.51% | 33.38% |
| Total Operating Expenses | -11.06% | -13.57% | -12.74% | -9.64% | -9.18% |
| Operating Income | 11.04% | -7.12% | -7.41% | -32.35% | -31.88% |
| Income Before Tax | -46.18% | -7.31% | -0.36% | -25.51% | -28.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.18% | -7.31% | -0.36% | -25.51% | -28.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.18% | -7.31% | -0.36% | -25.51% | -28.13% |
| EBIT | 11.04% | -7.12% | -7.41% | -32.35% | -31.88% |
| EBITDA | 11.75% | -8.22% | -8.00% | -35.25% | -33.96% |
| EPS Basic | -36.57% | -5.48% | 1.26% | -23.66% | -25.86% |
| Normalized Basic EPS | 32.74% | 19.44% | 21.11% | 4.71% | -53.59% |
| EPS Diluted | -36.57% | -5.48% | 1.26% | -23.66% | -25.86% |
| Normalized Diluted EPS | 32.74% | 19.44% | 21.11% | 4.71% | -53.59% |
| Average Basic Shares Outstanding | 4.18% | 1.82% | 1.62% | 1.50% | 1.58% |
| Average Diluted Shares Outstanding | 4.18% | 1.82% | 1.62% | 1.50% | 1.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
